48 CHAPTER 2 Extended Data Table 2. Opened cohorts (continued) Treatment Cohorts (incl. tumor type, tumor profile, and number of evaluable/enrolled patients) Trametinib ACUP MAP3K1mut 1/1 Cervical MAP3K1mut 1/1 CRC MAP2K1mut 2/2 CRC MAP2K4mut 1/1 NEC MAP3K1mut 1/1 NSCLC MEK1mut 3/3 NSCLC NRASmut 2/2 Ovarian NRASmut 1/1 Trastuzumab Pertuzumab Bladder ERBB2amp 2/2 Cervical ERBB2amp 2/2 Cervical ERBB2mut 1/1 Cholangio ERBB2amp 1/1 CRC ERBB2amp 7/7 CRC ERBB2mut 0/1 Hydradeno. ERBB2amp 1/1 NSCLC ERBB2amp 5/6 NSCLC ERBB2mut 13/15 Ovarian ERBB2amp 1/1 Ovarian ERBB2mut 1/1 Salivary ERBB2amp 3/4 Vulva ERBB2amp 1/1 Vemurafenib Cobimetinib ACUP BRAFmut 1/1 Ovarian BRAFmut 2/2 Salivary BRAFmut 2/2 Thyroid BRAFmut 2/2 Vismodegib Sarcoma PTCH1mut 1/1
RkJQdWJsaXNoZXIy MTk4NDMw